{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-036914","form_type":"8-K","ticker":"SPRY","cik":"0001671858","company_name":"ARS Pharmaceuticals, Inc.","filed_at":"2023-02-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.085085+00:00","generated_at":"2026-06-19T14:03:27.717359+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"medium","headline":"ARS Pharma reports $275M cash as of Dec 31, 2022; updates corporate presentation","bullets":["Cash and securities of approximately $275 million as of December 31, 2022.","Updated corporate presentation (Exhibit 99.1) highlights needle-free epinephrine solution for allergic reactions.","No additional financial results, guidance, or operational milestones disclosed in this filing."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-036914","json":"https://secwatch.observer/filing/0001193125-23-036914.json","markdown":"https://secwatch.observer/filing/0001193125-23-036914.md","text":"https://secwatch.observer/filing/0001193125-23-036914.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671858/000119312523036914/0001193125-23-036914-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671858/000119312523036914/d430763d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T14:03:27.717359+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}